Dr. Jason Dyck Joins Aurora's Board of Directors

VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 10, 2015) - Aurora Cannabis Inc. (CSE:ACB) (FRANKFURT:21P) (WKN:A1C4WM) (OTC:PSNTF) ("Aurora" or the "Company") is pleased to announce the appointment of Dr. Jason Dyck, PhD, to its Board of Directors.

Dr. Dyck is a distinguished research scientist in the Department of Pediatrics at the University of Alberta who specializes in the molecular biology of heart disease and metabolism. Dr. Dyck has over 160 peer-reviewed research publications and has a wealth of experience in establishing and directing large research programs. Dr. Dyck currently directs the University of Alberta Cardiovascular Research Centre and co-directs the pan-Alberta program known as Alberta HEART. Dr. Dyck's program and collaborative research is interdisciplinary, translational, and influential. This provides the strongest foundation for credible and useful research to reach key stakeholders and improve healthcare and health outcomes.

At the national/international level, Dr. Dyck is Chair of a Heart and Stroke Foundation Scientific Review Committee and Chair of a Canadian Diabetes Association Scientific Review Committee. He sits on the Editorial boards of 4 major international journals, reviews manuscripts for over 10 top tier journals and reviews grants for the National Institute for Health, the Welcome Trust, the National Health and Medical Research Council of Australia and the Dutch Diabetes Research Foundation. His world leading research on resveratrol led to his appointment on the International Working Group for Recommendations for Use of Resveratrol. Dr. Dyck is also a board member of the premier international cardiovascular metabolism society, The Society for Heart and Vascular Metabolism.

Not only is Dr. Dyck an outstanding research scientist and a leader in his field but he also has extensive experience in drug discovery and commercialization. He co-founded a successful University of Alberta spin-off company, currently holds more than 100 patents and has numerous collaborations with large pharmaceutical companies. His accomplishments in academic research, drug discovery and product/technology commercialization have contributed to Dr. Dyck being recognized as one of Canada's Top 40 under 40 (awarded by the Caldwell Partners in 2007), which is "presented to exceptional Canadians under the age of 40 who are outstanding leaders in their chosen fields and who are shaping our country's future".

Of particular importance to Aurora, Dr. Dyck has conducted comprehensive research into the beneficial health effects of the nutraceutical resveratrol (a bioactive compound found in plant- based food sources). This research represents a synergy which bridges the gap in the challenge of understanding plants-as-medicine, something currently lacking in the potential applications of medical cannabis.

Terry Booth, CEO of Aurora said, "Dr. Dyck's rich b ackground in research, applied science, publishing, pharmaceutical experience, business development and leadership brings crucial experience to the Aurora Cannabis Research Council and the Board by bridging the gap between discovery research, cannabis research and ultimately human health."

On behalf of the Board of Directors,

AURORA CANNABIS INC.

Terry Booth, CEO

The CSE, securities commission or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.